Poseida's Solid Tumor CAR-T Candidate Data Fails To Impress Investors
- The death of a patient in a solid tumor trial hit Poseida Therapeutics Inc (NASDAQ: PSTX) hard last August, but since then, the hold has been lifted, and it is now reporting some early data from that same therapy.
- The Company announced interim results for P-PSMA-101, solid tumor autologous CAR-T product candidate for metastatic castrate-resistant prostate cancer (mCRPC).
- The Company was bullish on the presentation today, but investors apparently were not impressed. The caveat is that it is Phase 1 trial with only heavily pretreated nine patients.
- Investigators tracked a significant, 50%-plus drop in Prostate-Specific Antigen (PSA) levels in 3 of those patients.
- One patient had a complete response at the lowest dose. Perhaps just as much as efficacy, safety will be keenly watched.
- Three cases of low-grade possible Cytokine Release Syndrome were observed, managed well with early treatment.
- No cases of neurotoxicity were observed as of the cutoff date.
- Related Content: Poseida's Fully Allogeneic CAR-T Product Enters Human Trial For Multiple Myeloma.
- Price Action: PSTX shares are down 17.1% at $8.88 during the market session on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: BriefsBiotech News Health Care Small Cap Movers Trading Ideas General
